rs1042713
Variant summary
Our verdict is Benign. Variant got -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_000024.6(ADRB2):c.46G>A(p.Gly16Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.388 in 1,613,480 control chromosomes in the GnomAD database, including 123,825 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as drug response (★★★). Another nucleotide change resulting in same amino acid change has been previously reported as Likely benignin UniProt.
Frequency
Consequence
NM_000024.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ADRB2 | NM_000024.6 | c.46G>A | p.Gly16Arg | missense_variant | 1/1 | ENST00000305988.6 | NP_000015.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ADRB2 | ENST00000305988.6 | c.46G>A | p.Gly16Arg | missense_variant | 1/1 | NM_000024.6 | ENSP00000305372 | P1 |
Frequencies
GnomAD3 genomes AF: 0.426 AC: 64762AN: 152090Hom.: 14124 Cov.: 35
GnomAD3 exomes AF: 0.421 AC: 105701AN: 251152Hom.: 22853 AF XY: 0.418 AC XY: 56692AN XY: 135786
GnomAD4 exome AF: 0.384 AC: 561623AN: 1461272Hom.: 109675 Cov.: 69 AF XY: 0.385 AC XY: 280174AN XY: 726918
GnomAD4 genome AF: 0.426 AC: 64831AN: 152208Hom.: 14150 Cov.: 35 AF XY: 0.431 AC XY: 32097AN XY: 74416
ClinVar
Submissions by phenotype
salmeterol response - Efficacy Other:1
drug response, reviewed by expert panel | curation | PharmGKB | Mar 24, 2021 | PharmGKB Level of Evidence 2A: Variants in Level 2A clinical annotations are found in PharmGKB’s Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2A clinical annotations must be supported by at least two independent publications. Drug-variant association: Efficacy |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at